Aceragen, Inc. to Delist from The Nasdaq Stock Market
04. August 2023 16:30 ET
|
Aceragen, Inc.
DURHAM, N.C. and EXTON, Pa., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Aceragen, Inc. (the “Company”) (Nasdaq: ACGN), announced today that the Company intends to voluntarily terminate the listing of its...
Aceragen, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing
30. Mai 2023 16:25 ET
|
Aceragen, Inc.
DURHAM, N.C. and EXTON, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Aceragen, Inc. (the “Company”) (Nasdaq: ACGN), announced today that on May 24, 2023, the Company received a notice from The Nasdaq Stock...
Aceragen Announces Recommendation of Data Monitoring Committee in Terra Study
06. Februar 2023 09:25 ET
|
Aceragen, Inc.
DURHAM, N.C. and EXTON, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Aceragen, Inc. (Nasdaq: ACGN) a clinical-stage biopharmaceutical company committed to transforming the care of people living...
Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook
17. Januar 2023 08:00 ET
|
Idera Pharmaceuticals, Inc.
Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple...
Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
14. November 2022 16:05 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and...
Idera Pharmaceuticals Acquires Aceragen
28. September 2022 16:09 ET
|
Idera Pharmaceuticals, Inc.
Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00...
Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results
09. August 2022 16:15 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the...
Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC
17. Mai 2022 08:04 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” “we,” and “our”) (Nasdaq: IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit...
Idera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
05. Mai 2022 16:15 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the...
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
31. März 2022 16:15 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the...